Hover over photographs to find out more
Co-Founder and Chief Executive Officer
Reuben holds 18 years of commercial biopharmaceutical industry experience.
Prior to co-founding Link Biologics, Reuben worked for Novo Nordisk in various leadership roles including Business Unit Head, Global Life Cycle Management Lead for a >$1bn product portfolio, and Global Product Director for multiple early-stage assets targeting billion-dollar markets.
.
Reuben holds an MSc in Drug Design from University College London (UCL).
Co-Founder & Scientific Director
Caroline is a Senior Lecturer in Immune Response
& Disease at the University of Manchester, where she is also the Lead for Postgraduate Research within the Division of Cell Matrix Biology and
Regenerative Medicine.
Caroline holds a DPhil in Biochemistry from the University of Oxford and has expertise in protein expression, molecular and cellular biology, and in vivo models. She has worked on TSG-6 for >20 years, co-leading multiple basic research and translational programmes and securing
significant funding.
Co-Founder & Chief Technology Officer
Tony is a Professor of Biochemistry within the Manchester Cell-Matrix Centre (University of Manchester), where he is Lead for Translation.
Tony was elected to the Academy of Medical Sciences in 2025, the Academy of Europe in 2012 and was formerly a member of the Council of the International Society for Matrix Biology (2016-2019) and President of the International Society for Hyaluronan Sciences (2021-2023).
Tony holds a DPhil in Biochemistry from the University of Oxford and has worked on TSG-6 for >30 years.
Chief Financial
Officer (Fractional)
Julia Jones is the Chief Financial Officer (Fractional) at Link Biologics and brings more than 25 years of financial leadership experience supporting innovative life sciences companies. A Chartered Accountant, she began her career at PricewaterhouseCoopers before founding Archangel Accounting Ltd, where she advises biotech and pharmaceutical companies from early-stage development through to exit.
Julia has extensive experience in strategic fundraising, venture-backed financial planning and transaction support, and has helped companies secure more than £1.2 billion in venture capital. She plays a key role in guiding Link Biologics’ financial strategy as the company advances its TSG-6-based therapeutic pipeline.
Associate Scientific Director
Nikos is a biochemist with over 15 years of experience in protein engineering, inflammation, and translational biology research.
Prior to joining Link Biologics, Nikos held postdoctoral positions at the Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, and the Hellenic Pasteur Institute, where he led projects on therapeutic proteins for inflammatory diseases.
Nikos holds a PhD in Biochemistry from the University of Nottingham.
Programme and Non-Clinical Director
Lorna holds over 20 years of biopharmaceutical R&D experience across academic and industry sectors.
Prior to joining Link Biologics, Lorna served as R&D Director at Cambrian Bio, Associate Director of Research at Oxstem, and Principal Scientist & Programme Manager at e-therapeutics, where she led multidisciplinary teams from early discovery through to clinical strategy.
Lorna holds a PhD in Cell Biology from Cardiff University.
Senior Clinical Lead
Majid is an ophthalmologist by training with over 25 years of experience in ophthalmology drug development and medical affairs.
Before joining Link Biologics, Majid served as VP of Clinical Development at OcuTerra Therapeutics, where he led an early-stage programme for diabetic retinopathy. Throughout his career, he has held senior clinical leadership positions, including Global Clinical Lead at Bayer and Allergan, Program Lead at Novartis, and senior roles at Roche, where he directed the development of therapies across both front- and back-of-the-eye indications.
Operations Assistant
Sophie contributes to the operational and scientific activities at Link Biologics. She combines scientific knowledge with organisational expertise, drawing on her education and experience in private healthcare operations.
She holds a BSc in Biological Sciences and an MSc in Genomic Medicine from King’s College London.
Board
Member
Céline Olmiere, PhD, is Head of Théa Open Innovation (TOI), where she leads the identification and evaluation of new assets and partnerships to expand the company’s pipeline and scientific network. She also leads Sepul Bio, a Théa business unit focused on developing therapies for inherited retinal diseases and serves on the boards of several life science companies.
Prior to joining TOI, Céline held roles of increasing responsibility at Laboratoires Théa, ultimately serving as Chief Scientific Officer, where she led the non-clinical department (pharmacology and toxicology) and scientific assessments for the Théa Group. She has 20 years of experience in ophthalmology R&D and has contributed to the registration and launch of numerous products.
Céline received her PhD in Molecular and Cellular Biology from Claude Bernard University in Lyon, and she serves as a Board Member of
Link Biologics.
Board Member
Dr Niall Martin is an industry pioneer in drug discovery, development, and biotech entrepreneurship with more than 20 years of experience.
He was CEO and Co-Founder of Artios Therapeutics, where he led the advancement of a DNA damage response platform into clinical development, raising over £300 million, and previously co-founded MISSION Therapeutics, where he raised over £80 million in Series A and B financing. Earlier in his career at KuDOS Pharmaceuticals (AstraZeneca), he co-invented the first-in-class PARP inhibitor olaparib (Lynparza), a landmark targeted therapy.
Dr Martin brings deep expertise in strategy, drug development and financing, and serves as a Board Member of Link Biologics, supporting the progression of its TSG-6-based therapeutic pipeline.
Co-Founder and
Chief Executive Officer
Reuben holds 18 years of commercial biopharmaceutical industry experience.
Prior to co-founding Link Biologics, Reuben worked for Novo Nordisk in various leadership roles including Business Unit Head, Global Life Cycle Management Lead for a >$1bn product portfolio, and Global Product Director for multiple early-stage assets targeting billion-dollar markets.
Reuben holds an MSc in Drug Design from University College London (UCL).
Co-Founder and
Chief Technology Officer
Tony is a Professor of Biochemistry within the Manchester Cell-Matrix Centre (University of Manchester), where he is Lead for Translation.
Tony was elected to the Academy of Medical Sciences in 2025, the Academy of Europe in 2012 and was formerly a member of the Council of the International Society for Matrix Biology (2016-2019) and President of the International Society for Hyaluronan Sciences (2021-2023).
Tony holds a DPhil in Biochemistry from the University of Oxford and has worked on TSG-6 for >30 years.
Chief Financial
Officer (Fractional)
Julia Jones is the Chief Financial Officer (Fractional) at Link Biologics and brings more than 25 years of financial leadership experience supporting innovative life sciences companies. A Chartered Accountant, she began her career at PricewaterhouseCoopers before founding Archangel Accounting Ltd, where she advises biotech and pharmaceutical companies from early-stage development through to exit.
Julia has extensive experience in strategic fundraising, venture-backed financial planning and transaction support, and has helped companies secure more than £1.2 billion in venture capital. She plays a key role in guiding Link Biologics’ financial strategy as the company advances its TSG-6-based therapeutic pipeline.
Programme Director and
Head of Non-Clinical
Lorna holds over 20 years of biopharmaceutical R&D experience across academic and industry sectors.
Prior to joining Link Biologics, Lorna served as R&D Director at Cambrian Bio, Associate Director of Research at Oxstem, and Principal Scientist & Programme Manager at e-therapeutics, where she led multidisciplinary teams from early discovery through to clinical strategy.
Lorna holds a PhD in Cell Biology from Cardiff University.
Co-Founder and
Scientific Director
Caroline is a Senior Lecturer in Immune Response & Disease at the University of Manchester, where she is also the Lead for Postgraduate Research within the Division of Cell Matrix Biology and Regenerative Medicine.
Caroline holds a DPhil in Biochemistry from the University of Oxford and has expertise in protein expression, molecular and cellular biology, and in vivo models. She has worked on TSG-6 for >20 years, co-leading multiple basic research and translational programmes and securing significant funding.
Associate
Scientific Director
Nikos is a biochemist with over 15 years of experience in protein engineering, inflammation, and translational biology research.
Prior to joining Link Biologics, Nikos held postdoctoral positions at the Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, and the Hellenic Pasteur Institute, where he led projects on therapeutic proteins for inflammatory diseases.
Nikos holds a PhD in Biochemistry from the University of Nottingham.
Operations Assistant
Sophie supports the operational and scientific activities at Link Biologics.
She holds a BSc in Biological Sciences and an MSc in Genomic Medicine from King’s College London. Her background, along with educational studies, include molecular biology laboratory research and experience in private healthcare operations, bringing a strong blend of both scientific knowledge and organisational expertise to the team.
Board
Member
Céline Olmiere, PhD, is Head of Théa Open Innovation (TOI), where she leads the identification and evaluation of new assets and partnerships to expand the company’s pipeline and scientific network. She also leads Sepul Bio, a Théa business unit focused on developing therapies for inherited retinal diseases and serves on the boards of several life science companies.
Prior to joining TOI, Céline held roles of increasing responsibility at Laboratoires Théa, ultimately serving as Chief Scientific Officer, where she led the non-clinical department (pharmacology and toxicology) and scientific assessments for the Théa Group. She has 20 years of experience in ophthalmology R&D and has contributed to the registration and launch of numerous products.
Céline received her PhD in Molecular and Cellular Biology from Claude Bernard University in Lyon, and she serves as a Board Member of Link Biologics.
Board
Member
Dr Niall Martin is an industry pioneer in drug discovery, development, and biotech entrepreneurship with more than 20 years of experience.
He was CEO and Co-Founder of Artios Therapeutics, where he led the advancement of a DNA damage response platform into clinical development, raising over £300 million, and previously co-founded MISSION Therapeutics, where he raised over £80 million in Series A and B financing. Earlier in his career at KuDOS Pharmaceuticals (AstraZeneca), he co-invented the first-in-class PARP inhibitor olaparib (Lynparza), a landmark targeted therapy.
Dr Martin brings deep expertise in strategy, drug development and financing, and serves as a Board Member of Link Biologics, supporting the progression of its TSG-6-based therapeutic pipeline.
124 City Road, London, EC1V 2NX, U.K.
Registered in England and Wales. Registration no. 12550888
